Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06046248 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 4 versions Re-verified since Oct 16, 2024, no change to tracked fieldsv4-v7
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 31, 2023 to Jan 29, 2024
    • Site details revised
    v3
  3. Primary endpoint revised
    • Secondary endpoints revised (2)
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Trial Details
NCT Number NCT06046248
Lead Sponsor Northside Hospital, Inc.
Collaborators: Sanofi
Conditions
(from sponsor)		 Chronic Graft Versus Host Disease
Related terms Bronchiolitis Obliterans Syndrome
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov